未接种更新版新冠疫苗临床预测工具的开发和验证
在Kaiser Permanente南加州人群3287287名成人中,20.2%接种了2023-2024年新冠疫苗。研究基于电子健康记录中15个变量构建未接种预测模型,开发样本C统计量为0.882,验证样本表现相似,简化的6变量和2变量模型表现也相似。最强预测因素为既往未接种二价新冠疫苗或流感疫苗。
要点
- 在3287287名成人中,20.2%接种了2023-2024年新冠疫苗。
- 15变量模型开发样本C统计量0.882,验证样本表现相似。
- 最强预测因素为既往未接种二价新冠疫苗或流感疫苗。
核心结论
- 使用医疗保健提供者可获得的变量构建的简单模型,可优化以指导更新版新冠疫苗的干预策略。
研究设计与样本
- 在Kaiser Permanente南加州开发并验证未接种更新版新冠疫苗的预测模型,纳入3287287名成人,评估电子健康记录中15个变量与未接种2023-2024年更新版新冠疫苗的关联,队列分为开发样本和验证样本。
主要发现
- 3287287名成人中,20.2%接种了2023-2024年新冠疫苗。
- 15变量模型在开发样本中表现中等,缩放Brier分数为35.6%,R2为29.3%,C统计量为0.882,区分度斜率为0.354,校准斜率为1。
- 验证样本表现与开发样本相似,简化的6变量和2变量模型表现也相似。
- 最强预测因素为既往未接种二价新冠疫苗或流感疫苗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination with updated COVID-19 vaccines is important to maintain protection against circulating SARS-CoV-2 variants. We developed and validated a prediction model for non-receipt of updated COVID-19 vaccines at Kaiser Permanente Southern California. Of 3,287,287 adults, 20.2 % received 2023-2024 COVID-19 vaccine. We assessed the association of 15 variables available in electronic health records with non-receipt of 2023-2024 updated COVID-19 vaccine. The cohort was split into development and validation samples. Performance of the 15-variable model in the development sample was moderate, with a scaled Brier score of 35.6 %, R2 of 29.3 %, C-statistic of 0.882, discrimination slope of 0.354, and calibration slope of 1; performance was similar for the validation sample and simplified 6-variable and 2-variable models. The strongest predictors were prior non-receipt of bivalent COVID-19 vaccine or influenza vaccine. These results suggest that a simple model using variables available to healthcare providers can be optimized to guide intervention strategies for updated COVID-19 vaccines.
引用
- Bruxvoort KJ, Sy LS, Contreras R, et al. Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccines. Vaccine. 2025. PMID: 40215705. doi:10.1016/j.vaccine.2025.127074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。